MARTH, C. Olaparib shows significant progression-free survival benefit in phase III SOLO2 trial:  . Cancer Breaking News, [S. l.], v. 5, n. 2, p. 3–4, 2017. DOI: 10.19156/cbn.2017.0041. Disponível em: https://journals.aboutscience.eu/index.php/cancerbreakingnews/article/view/177. Acesso em: 23 nov. 2024.